629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor

629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor

Bibliographic Details
Main Authors: Jameel Muzaffar, Tae Min Kim, Julie Brahmer, Dirk G Brockstedt, Chia-Chi Lin, Michael Chisamore, Ki Hyeong Lee, Paul D Kassner, Nuttapong Ngamphaiboon, William Ho, Nicole Nasrah, Pratibha Desai, Yin-Hsun Feng, Shang-Yin Wu, Rakesh Kumar Goyal
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items